CLINICAL TRIALS PROFILE FOR NULYTELY
✉ Email this page to a colleague
All Clinical Trials for NULYTELY
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00164151 ↗ | A Comparison of the Efficacy and Safety of HalfLytely Vs Visicol Prior To Colonoscopy. | Completed | Braintree Laboratories | Phase 3 | 2001-06-01 | The objective of this study is to determine the efficacy and safety of HalfLytely as compared to Visicol as bowel preparations before colonoscopic examination. |
| NCT00164164 ↗ | HalfLytely Bowel Prep System for Colonoscopy | Completed | Braintree Laboratories | Phase 3 | 1999-08-01 | The purpose of the this study was to compare the safety and efficacy of HalfLytely (2L NULYTELY + 20mg bisacodyl) to NULYTELY for preparation prior to colonoscopy. |
| NCT00425594 ↗ | A Safety and Efficacy Evaluation of 3 Bowel Preparations in the Pediatric Population | Completed | Braintree Laboratories | Phase 4 | 2007-01-01 | This randomized, parallel, multi-center, single-blind study is designed to compare the safety and efficacy of 3 bowel preparations in pediatric subjects scheduled to undergo a colonoscopy for a routinely accepted indication. |
| NCT00689026 ↗ | Efficacy of Lubiprostone in Combination With Standard PEG Preparation | Terminated | Takeda Pharmaceuticals North America, Inc. | N/A | 2008-05-01 | A large population-based study has shown diabetes to be an independent risk factor for colon cancer compared to the general population. Thus, the completion of an adequately prepped colonoscopy is requisite in providing diabetics with adequate colon cancer screening. Recent data has shown that diabetic patients have poorer response to bowel cleansing compared to non-diabetics (with a standard PEG prep, only 62% of diabetic patients had their colonoscopy preps rated as good or better vs. 97% of normal patients, p<0.001). This may be due to the fact that a majority of diabetic patients report constipation as a common gastrointestinal complaint. We postulate that lubiprostone (Amitiza), in combination with PEG, will have additional efficacy over standard PEG preparation, and provide optimal safe and effective colonic cleansing for diabetics. |
| NCT00689026 ↗ | Efficacy of Lubiprostone in Combination With Standard PEG Preparation | Terminated | Augusta University | N/A | 2008-05-01 | A large population-based study has shown diabetes to be an independent risk factor for colon cancer compared to the general population. Thus, the completion of an adequately prepped colonoscopy is requisite in providing diabetics with adequate colon cancer screening. Recent data has shown that diabetic patients have poorer response to bowel cleansing compared to non-diabetics (with a standard PEG prep, only 62% of diabetic patients had their colonoscopy preps rated as good or better vs. 97% of normal patients, p<0.001). This may be due to the fact that a majority of diabetic patients report constipation as a common gastrointestinal complaint. We postulate that lubiprostone (Amitiza), in combination with PEG, will have additional efficacy over standard PEG preparation, and provide optimal safe and effective colonic cleansing for diabetics. |
| NCT00953043 ↗ | Lubiprostone, Colonic Motility and Sensation | Completed | National Center for Research Resources (NCRR) | Phase 4 | 2007-09-01 | This study is being done to evaluate the effects of lubiprostone, a drug approved and used for constipation, on pattern of contractions of the colon and the colon's sensitivity to distension. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NULYTELY
Condition Name
Clinical Trial Locations for NULYTELY
Trials by Country
Clinical Trial Progress for NULYTELY
Clinical Trial Phase
Clinical Trial Sponsors for NULYTELY
Sponsor Name
